Phase III, Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate Tozorakimab in Participants with COPD with a History of COPD Exacerbations (MIRANDA)

Investigator: Rodney Folz, MD

Study Coordinator: Mayyadah al-Sabbagh

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT06040086

Phone: 346.238.0024

Protocol Number: PRO00038076

Description

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab300 mg administered subcutaneously (SC) every 2 weeks (Q2W) in adult participants with symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a history of = 2 moderate or = 1 severe exacerbations of COPD in the 12 months prior to enrolment.
More to Explore